Professional Documents
Culture Documents
Charcot arthropathy of the foot is a rare but devastating complication of diabetes that remains to be a
challenging issue for the foot and ankle surgeons. Charcot foot fails to be an obvious diagnostic option that
comes to mind, even in a pathognomonic clinical appearance. The rarity of the disorder, more common
pathologies that mimic the condition, and the self-limiting prognosis deviate the clinician from the right
diagnosis. The clinical challenges in the diagnosis of Charcot foot require in-depth investigations of its
enigmatic nature to establish useful guidelines. Yet, this goal seems to be beyond reach, without a holistic
view of the immense literature concerning the pathophysiology of the disorder. The primary objective of this
article is to put together and review the recent advancements about the etiology and intrinsic mechanisms
of diabetic Charcot foot.
Keywords: Charcot foot; pathophysiology; diabetes mellitus; neuropathy; neuropeptides
Received: 12 April 2013; Revised: 9 June 2013; Accepted: 1 July 2013; Published: 2 August 2013
europathic arthropathy, also referred as Charcot revealed. Yet, the rarity of the condition, its asymmetric
Diabetic Foot & Ankle 2013. # 2013 Gökhan Kaynak et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution- 1
Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction
in any medium, provided the original work is properly cited. Citation: Diabetic Foot & Ankle 2013, 4: 21117 - http://dx.doi.org/10.3402/dfa.v4i0.21117
(page number not for citation purpose)
Gökhan Kaynak et al.
results in microfractures, escalating into macrofractures Due to the lack of specific markers or diagnostic criteria
that eventually end up in massive joint destruction with and Charcot artropathy’s clinical resemblance to rela-
characteristic clinical presentation (Figs. 1 and 2) (17, 18). tively more common disorders such as osteomyelitis, the
However, recent studies demonstrated that the loss of diagnosis is missed or delayed in 25% of the cases (28).
proprioception is not the only etiological factor that leads Yet, an increase in the incidence of Charcot arthropathy
to Charcot arthropathy (19). The intervention of certain has been reported in recent studies. This increase can
external factors, usually unrecognized or irrelevant to the be explained by the progress made at the diagnostic
diabetes, or any other predisposing disease, is a factor modalities, the rising awareness of the condition amongst
that leads to a local increase in blood flow. Therefore, the physicians and caregivers, and the decreasing rate
the patient’s peripheral circulation should be capable of of lower limb amputations due to improved hospital
vasodilatating despite widespread atherosclerosis, which cares (24).
explains why Charcot foot is frequent in a relatively A prospective study conducted in Singapore with
younger population. In summary, to develop a Charcot 202 diabetic patients revealed that 42.1% of the patients
syndrome, it is understood that a patient should have a had sensory neuropathy and 2% of them had Charcot
peripheral neuropathy to enhance a local inflammation arthropathy (29). The incidences of Charcot foot in type
that is triggered by a minor injury, infection, operation, 1 and type 2 diabetes do not differ, although osteopenia,
or an earlier ulceration (1, 20). as a predisposing factor, appears to be more prevalent
Presently, diabetes is recognized as one of the most in type 1 (18, 20). However, Petrova et al. reported a
common cause of denervation-induced arthropathy difference in the presentation of Charcot arthropathy at
worldwide (18, 2023), the exception is for leprosy, which type 1 and type 2 diabetic patients. In a more recent study,
appears to be a more common cause of the Charcot foot in the same authors emphasized a relative preponderance of
endemic areas (6, 7, 24). In the European Diabetes Centers type 1 diabetes compared with type 2 (18, 30). Although
study of complications in patients with insulin-dependent the unilaterality of the condition is emphasized in many
diabetes mellitus (EURODIAB IDDM), in which a con- clinical studies, acute Charcot arthropathy is reported
siderable number of diabetic patients were included, the as bilateral in 9% of the patients (31). Moreover, after
overall prevalence of neuropathy was 28% (25). Never- prospective computerized tomography examinations,
theless, the incidence of Charcot arthropathy is relatively bilateral neuroarthropathic changes are demonstrated in
rare, even in neuropathic patients. Charcot arthropathy’s 75% of Charcot patients (17). Chisholm and colleagues
estimated prevalence is approximately 1% of all neuro- suggest that obesity is also a predisposing factor for
pathic patients (20). Addressing this rarity, Jeffcoate Charcot arthropathy since at least two thirds of Charcot
explains that Charcot arthropathy develops or progresses patients are obese (22, 32).
in a small subset of patients where a number of predis- Trauma is the most common etiological factor encoun-
posing factors coexist (26). The prevalence of diagnosed tered in the pathogenesis of Charcot arthropathy and was
Charcot arthropathy in patients with diabetes is reported reported to be present in 2253% of the cases (6, 17, 18).
to be 0.087.5% (3). However, some studies suggest higher Capillary leakage and subsequent formation of edema is
prevalence with as many as 13% of all diabetic patients the physiological response to blunt trauma (33). A higher
and 29% of the neuropathic patients affected (22, 27). energy trauma causes a disruption of marrow trabeculae
2
(page number not for citation purpose)
Citation: Diabetic Foot & Ankle 2013, 4: 21117 - http://dx.doi.org/10.3402/dfa.v4i0.21117
The Charcot foot
leading to interstitial fluid and hemorrhage accumula- first year of transplantation where high glucocorticoid
tion to marrow spaces, hence a bone bruise. When this intake was the main factor leading to bone resorption
condition occurs in the foot of a non-diabetic patient, it is and myofibril proteolysis (37).
painful and following the cessation of ambulation, local
inflammation of the foot subsides. But in a neuropathic Pathophysiology
patient, the insensitive foot does not exhibit pain as The well-respected neurotraumatic and neurotrophic
appropriate. Thus, lack of required immobilization flares theories have been relied on for a long time in order to
up the inflammatory cycle (26). clarify the pathogenesis of Charcot arthropathy. But
Osteomyelitis and surgery may initiate Charcot arthro- none of these theories can explain this pathogenesis by
pathy in predisposing backgrounds (34). As mentioned themselves. Nevertheless, as the research advanced,
before, osteomyelitis can imitate the clinical appearance neither the neurotrophic theory which was represented
of Charcot arthropathy and consequently lead to mis- by Charcot himself (22) nor the neurotraumatic theory
diagnosis and under-treatment. One third of the diabetic which was supported mainly by German scientists,
foot infections are complicated by osteomyelitis which is have lost value. On the contrary, as complex biochemical
due to direct contamination from a soft, tissue ulcer (35). processes revealed, the pathways of the two theories
Osteomyelitis manifests with local inflammation and pro- became more and more intertwined (22, 27).
gressive destruction of the bone which in turn intensify Charcot, who first studied disturbed physiological
the proinflammatory cascade. processes that end up to neuropathic arthropathy, pre-
Local surgery of the foot is suggested as one of the sented the neurovascular theory (38). He believed that
triggering factors of Charcot arthropathy (26, 36). Arm- irritation of the ‘trophic’ or vasomotor nerve centers
strong et al. retrospectively observed data from 55 acute caused an alteration of bone and joint nutrition. This
Charcot arthropathy patients and reported that 4% of the theory has been carried further by his supporters, and
patients had recent foot surgery as the only etiological now it suggests that autonomic neuropathy disregulates
factor (31). Charcot arthropathy may also follow injudi- smooth muscle tonus on the arterial wall. Thus, it leads
cious immobilization after surgery, a long period of bed to a failure in vasoregulation and an increase in blood
rest or casting (18). Disobedience to a forbidden weight flow to the bone. Monocytes and osteoclasts storm the
bearing after foot surgery is also underlined in a case affected site and this accelerates the bone resorption rate
report as a possible cause of Charcot arthropathy (36). resulting in osteopenia. Lower structural resistance cause
Charcot arthropathy has also been reported following minor traumas to end up in fractures, dislocations, and
a simultaneous pancreas-kidney transplantation (SPKT) joint collapses (22). Volkman and Virchow confronted this
(37). In a more recent study where data from 130 SPKT theory, suggesting an insensate foot is prone to repetitive
patients without any previous history of Charcot arthro- unrecognized traumas (38). In addition to this, loss of
pathy were analyzed retrospectively, six patients (4.6%) proprioception disables the protective factors and causes
were diagnosed de novo Charcot arthropathy during the an abnormal joint loading. Multiple traumas and
instability result in joint deterioration. The contribution porosis, metastatic malignancy, periodontitis, prosthesis-
of each of the theories to the pathogenesis of Charcot foot related osteolysis, and rheumatoid arthritis (20, 26).
is broadly detailed and discussed below. RANKL activity is antagonized by Osteoprotegerin
(OPG), a soluble glycoprotein decoy receptor for RANK
Inflammation ligand which effectively neutralizes its effects (20).
Local inflammation is the indispensable factor that OPG’s expression is induced by NF-kB, as a self-limiting
triggers the course of events on a predisposing environ- agent of its proinflammatory function. The patients with
ment. The physiological balance between the pro and Charcot arthropathy displayed elevated RANKL/OPG
anti-inflammatory cytokines that restrains the inflamma- ratios fuelling the progression of the inflammation (Fig. 3)
tory response to a necessary extent is compromised in (41, 42).
Charcot patients. Baumhauer’s findings support this Osteoclasts play a key role in the course of Charcot
phenomenon based on the fact that in a Charcot patient arthropathy as executer cells, responsible for imbalanced
the modulation of immune system is disturbed in coun- bone turnover and eventually osteolysis. Macrophage
tenance of proinflammatory cytokines (6). Whatever is colony stimulating factor (M-CSF) is required for pre-
the stimulant, the bone and soft tissues respond with an cursor cells in myeloid lineage to differentiate into bone
acute-phase release of proinflammatory cytokines, tumor marrow macrophages, but the activation of NF-kB is
necrosis factor-a (TNFa), and interleukin-1b (IL-1b). crucial for their further differentiation, fusion into
They have found an increase in the amount of TNF-a, multinucleated osteoclasts, activation, and survival (41).
IL-1b, and interleukin-6 (IL-6), whereas a decrease in the However, the first cell line to dysfunction seems to be the
levels of interleukin-4 and interleukin-10 known as anti-
monocytes, the precursor cells of osteoclasts. With high
inflammatory cytokines (39). An abnormally intense and
levels of proinflammatory cytokines, monocytes stimulate
prolonged inflammatory response is inevitable under
T lymphocytes in an exaggerated way. In addition to
these circumstances.
this, monocytes obtained from Charcot patients present
Increased amounts of proinflammatory cytokines,
reduced secretion of anti-inflammatory cytokines, and
especially TNFa is found to be responsible for triggering
increased resistance to apoptosis (21, 42). This resistance
another cytokine pathway that is centered on the poly-
peptide, the receptor activator of nuclear factor-kB provided mainly by IL-1b and TNFa causes the persis-
(NF-kB) ligand (RANKL). As a member of the TNF tence of the abnormally intense and prolonged inflam-
superfamily, RANKL is the ligand that activates the matory response (3). Ndip et al. reported that IL-8 and
receptor of NF-kB (RANK). The activation of RANK Granulocyte-Colony Stimulating Factor (GCSF) were
stimulates the intracellular pathways that end up by inducing monocytes into an osteoclastic differentiation
formation of nuclear transcription factor NF-kB. The along with the RANKL/RANK pathway (41).
expression of NF-kB induces osteoclast precursor cells Pitocco et al. encountered a significant decrease in the
to differentiate into mature osteoclasts (20, 21). Thus, circulating levels of IGF-1 while investigating bipho-
NF-kB pathway is implicated in the excessive osteoclastic sphonate’s efficacy in Charcot patients (43). IGF-1 is a
activity in diabetic Charcot arthropathy (40, 41) along mediator of vasodilatation, and biphosphonate’s redu-
with its involvement in many conditions that manifest cing effect over IGF-1 could have a beneficial contribu-
with osteolysis including glucocorticoid-induced osteo- tion to restrain proceeding inflammation.
4
(page number not for citation purpose)
Citation: Diabetic Foot & Ankle 2013, 4: 21117 - http://dx.doi.org/10.3402/dfa.v4i0.21117
The Charcot foot
In Charcot arthropathy patients, exaggerated osteoclast A recent study demonstrated the development of
activity leads to an imbalance of constant remodeling Charcot arthropathy after administration of high doses
processes. An increase in alkaline phosphatase and of glucocorticoids (37). Glucocorticoids affect the bone
collagen residues, indicative of osteoclast activity, were turnover in countenance of resorption, and decreased bone
observed in the patients with acute Charcot arthropathy formation may trigger or worsen Charcot arthropathy.
(55, 56). However, in a recent study La Fontaine suggested Vitamin D deficiency is accused of being preliminary
the possibility of a preexisting abnormal bone structure to the development of Charcot arthropathy (37). Hypo-
predisposing diabetic patients for Charcot foot (5). calcaemia occurs in vitamin D deficiency and this
They have conducted histological examination of bone stimulates parathyroid hormone (PTH) which in turn
specimens obtained from diabetic patients and observed depletes calcium from the bone causing osteopenia. The
a distorted microstructure with fewer trabeculae and level of 1,25(OH)2D3 is significantly lower in diabetic
patients and this decrease results in a less mineralized
fewer cells. Thus, the authors argued that the degen-
bone formation, a smaller growth plate and an inade-
erative changes in the bone micro-architecture may not
quate turnover, all being reversed by insulin treatment (49).
be a consequence, but a cause of Charcot arthropathy
(Fig. 4) (5).
Hyperglycemia
Although a low bone mineral density (BMD) is
The expression of RANKL is proven to be closely
observed in patients with type 1 diabetes, the BMD is
associated with metabolic consequences of the diabetes.
similar to or higher in type 2 diabetic patients than in
Increased blood sugar potentiates free radical formation,
non-diabetic subjects (5). Yet, Charcot foot’s prevalence
hyperlipidemia and advanced glycation end-products
does not seem to preponderate between types of diabetes
(AGEs), triggering the RANK/RANKL cytokine system
(18, 20). Christensen et al. reported significantly lower (6). Moreover, an in vitro inhibitory effect of physiologi-
BMD values obtained from the affected foot of chronic cal concentrations of insulin on the NF-kB and mono-
Charcot patients whereas no difference was in the cal- cyte chemoattractant protein 1 (MCP-1) is also reported
caneal BMD between acute Charcot patients and the (57). This non-RANKL inhibitory mechanism is im-
control group. Therefore, Charcot arthropathy does not paired in diabetic patients who are deprived of insulin.
seem to affect the skeleton in general (57). Moreover, However, those pathways may not be majorly effective
biochemical indicators of bone turnover were also since the Charcot arthropathy is rare even in diabetic
evaluated in the same study and statistically significant neuropathy patients (58).
differences in osteocalcin concentrations reflecting in- Hyperglycemia denaturates tendons and ligaments
creased bone turnover were demonstrated in acute through a non-enzymatic collagen glycation. This phe-
Charcot foot (56). nomenon could cause tendon shortenings and thus,
6
(page number not for citation purpose)
Citation: Diabetic Foot & Ankle 2013, 4: 21117 - http://dx.doi.org/10.3402/dfa.v4i0.21117
The Charcot foot
redistribution of the plantar pressures abnormally (17). of neuropathic patients are spared from Charcot
Moreover, since collagen is a structural component of the arthropathy.
bone, AGE-related modifications of collagen, may impair Finally, it is often difficult to isolate and experiment
the mechanical properties of bone itself, predisposing it the contribution of a single factor in this complex and
to fractures and dislocations (49, 59) (Figs. 3 and 4). multifactorial phenomenon. This fact precludes the con-
struction of experimental models to reveal single factor
contributions or gathering of adequate (appropriate)
Genetics
control groups for blinded control studies. This suggestion
Genes regulating OPG/RANK/RANKL axis and their
can be adapted to Charcot foot that develops as a result of
polymorphisms have already been indicated in the patho-
a subsequent dysfunction concerning different systems
genesis of the osteoporosis (60). A correlation between
which cannot be separated and observed solely. This
diabetic Charcot arthropathy and OPG gene polymorph-
stalemate can be addressed with prospective studies and
isms is first suggested by Pitocco et al. (61). They have
a larger number of patients.
investigated single-nucleotide polymorphisms (SNPs) on
the OPG gene and found two variations that could result
in both qualitative and quantitative alterations of OPG. Conflict of interest and funding
A strong association with Charcot arthropathy and the The authors have received no funding or benefits from
polymorphisms of those alleles were also demonstrated. industry to conduct this study.
Recently, Korzon-Burakowska et al. supported this asso-
ciation in their study conducted in the Polish popula-
tion (28). Their results agreed with the previous study References
conducted in Italy (61), despite the differences in alleles
1. Jeffcoate W. The causes of the Charcot syndrome. Clin Podiatr
between Charcot patients and control groups did not Med Surg 2008; 25: 2942.
match among the two populations. 2. van der ven A, Chapman CB, Bowker JH. Charcot neuroar-
thropathy of the foot and ankle. J Am Acad Orthop Surg 2009;
17: 56271.
Discussion 3. Larson SA, Burns PR. The pathogenesis of Charcot neuroar-
The pathophysiological process that leads to an acute thropathy: current concepts. Diabet Foot Ankle 2012; 3: 12236.
4. Mabilleau G, Petrova N, Edmonds M, Sabokbar A. Increased
Charcot foot episode is a very dynamic research topic. osteoclastic activity in acute Charcot’s osteoarthropathy: the
New studies are added to the immense pool of literature role of receptor activator of nuclear factor-kappa B ligand.
on this topic aiming to clarify and prevent the onset Diabetologia 2008; 51: 103540.
and progression of this devastating complication. Recent 5. La Fontaine J, Shibuya N, Sampson HW, Valderrama P.
advances on the subject demonstrated that the neuro- Trabecular quality and cellular characteristics of normal,
diabetic, and Charcot bone. J Foot Ankle Surg 2011; 50: 64853.
traumatic and neurotrophic theories both play a part and 6. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflamma-
contribute to development of the Charcot foot. However, tory cytokines in the cause of neuropathic osteoarthropathy
the question that still remains is why all patients with (acute Charcot foot) in diabetes. Lancet 2005; 366: 205861.
diabetic neuropathy do not develop a Charcot foot? 7. Rostom S, Bahiri R, Mahfoud-Filali S, Hajjaj-Hassouni N.
Neurogenic osteoarthropathy in leprosy. Clin Rheumatol 2007;
A reasonable explanation to this question may enlighten
26: 21535.
the pathogenesis substantially and thus, set forth a 8. Panagariya A, Sharma AK. Bilateral Charcot arthropathy of
possible way to avoid its onset. shoulder secondary to syringomyelia: an unusual case report.
In recent studies, many authors have emphasized the Ann Indian Acad Neurol 2012; 15: 2024.
disturbance of the inflammatory cycle in the core of 9. Hatzis N, Kaar K, Wirth MA, Toro F, Rockwood CA Jr.
Charcot foot pathophysiology. Usually minor injuries Neuropathic arthropathy of the shoulder. J Bone Joint Surg Am
1998; 80: 13149.
which are even unrecognized, local infection or a minor 10. Kenan S, Lewis MM, Main WK, Hermann G, Abdelwahab IF.
surgery may prompt this sequence of events. Without the Neuropathic arthropathy of the shoulder mimicking soft tissue
protective behavior ensured by the pain, in the insensate, sarcoma. Orthopedics 1993; 16: 11336.
neuropathic foot of a diabetic patient this cycle is flared 11. Atalar AC, Sungur M, Demirhan M, Ozger H. Neuropathic
up by repeated traumatic events. Genetic variations that arthropathy of the shoulder associated with syringomyelia:
a report of six cases. Acta Orthop Traumatol Turc 2010; 44:
affect the balance between pre- and anti-inflammatory 32836.
chemo-attractants may predispose a patient to Charcot 12. Paliwal VK, Singh P, Rahi SK, Agarwal V, Gupta RK. Charcot
foot (28, 61). This theory which has been proposed by knee secondary to lumbar spinal cord syringomyelia: complica-
two different studies conducted in different populations tion of spinal anesthesia. J Clin Rheumatol 2012; 18: 2078.
is a breakthrough for researchers who dedicated their 13. Chopra K, Tiwari V. Alcoholic neuropathy: possible mecha-
nisms and future treatment possibilities. Br J Clin Pharmacol
work to Charcot foot. Genetic variations can explain a 2012; 73: 34862.
patient’s tendency to pro-inflammatory status, and ulti- 14. Altenburg N, Joraschky P, Barthel A, Bittnert A. Alcohol
mately may put forth a solid answer why a majority consumption and other psycho-social conditions as important
factors in the development of diabetic foot ulcers. Diabet Med 37. Rangel ÉB, Sá JR, Gomes SA, Carvalho AB, Melaragno CS.
2011; 28: 16874. Charcot neuroarthropathy after simultaneous pancreaskidney
15. Koike H, Sobue G. Alcoholic neuropathy. Curr Opin Neurol transplant. Transplantation 2012; 94: 6425.
2006; 19: 4816. 38. Charcot JM. Sur quelques arthropathies qui paraissent de-
16. Zambelis T, Karandreas N, Tzavellas E. Large and small fibre pendre d’une lésion du cerveau ou de la mouelle épinière. [On
neuropathy in chronic alcohol-dependent subjects. J Peripher some arthropathies apparently related to a lesion of the brain or
Nerv Syst 2005; 10: 37581. spinal cord]. Arch Physiol Norm Pathol 1868; 1: 16178.
17. Gouveri E, Papanas N. Charcot osteoarthropathy in diabetes: 39. Baumhauer JF, O’Keefe RJ, Schon LC, Pinzur MS. Cytokine
a brief review with an emphasis on clinical practice. World J induced osteoclastic bone resorption in Charcot arthropathy:
Diabet 2011; 2: 5965. an immunohistochemical study. Foot Ankle Int 2006; 27:
18. Petrova NL, Edmonds ME. Charcot neuro-osteoarthropathy 797800.
current standards. Diabetes Metab Res Rev 2008; 24: 5861. 40. Wang L, Shi X, Zhao R, Halloran BP, Clark DJ. Calcitonin-
19. Chantelau E, Onvlee GJ. Charcot foot in diabetes: farewell to gene-related peptide stimulates stromal cell osteogenic differ-
the neurotrophic theory. Horm Metab Res 2006; 38: 3617. entiation and inhibits RANKL induced NF-kappaB activation,
20. Jeffcoate W. Charcot neuro-osteoarthropathy. Diabetes Metab osteoclastogenesis and bone resorption. Bone 2010; 46: 136979.
Res Rev 2008; 24: S625. 41. Ndip A, Williams A, Jude EB, Serracino-Inglott F. The
21. Uccioli L, Sinistro A, Almerighi C, Ciaprini C. Proinflammatory RANKL/RANK/OPG signaling pathway mediates medial
modulation of the surface and cytokine phenotype of mono- arterial calcification in diabetic charcot neuroarthropathy.
cytes in patients with acute Charcot foot. Diabetes Care 2010; Diabetes 2011; 60: 218796.
33: 3505. 42. Mangan DF, Welch GR, Wahl SM. Lipopolysaccharide, tumor
22. Chisholm KA, Gilchrist JM. The Charcot joint: a modern necrosis factor-alpha, and IL-1 beta prevent programmed cell
neurologic perspective. J Clin Neuromusc Dis 2011; 13: 113. death (apoptosis) in human peripheral blood monocytes. J
23. Jones KB, Mollano AV, Morcuende JA. Bone and brain: a Immunol 1991; 146: 15416.
review of neural, hormonal, and musculoskeletal connections. 43. Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM. Six-
Iowa Orthop J 2004; 24: 12332. month treatment with alendronate in acute Charcot neuroar-
24. Rajbhandari SM, Jenkins RC, Davies C. Charcot neuroarthro- thropathy: a randomized controlled trial. Diabetes Care 2005;
pathy in diabetes mellitus. Diabetologia 2002; 45: 108596. 28: 12145.
25. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH. Prevalence of 44. Irie K, Hara-Irie F, Ozawa H, Yajima T. Calcitonin gene-related
diabetic peripheral neuropathy and its relation to glycaemic peptide (CGRP) -containing nerve fibers in bone tissue and their
involvement in bone remodeling. Microsc Res Tech 2002; 58:
control and potential risk factors: the EURODIAB IDDM
8590.
complications study. Diabetologia 1996; 39: 137784.
45. Imai S, Matsusue Y. Neuronal regulation of bone metabolism
26. Jeffcoate WJ. Abnormalities of vasomotor regulation in the
and anabolism: calcitonin gene-related peptide-, substance P-,
pathogenesis of the acute Charcot foot of diabetes mellitus. Int
and tyrosine hydroxylase-containing nerves and the bone.
J Low Extrem Wounds 2005; 4: 1337.
Microsc Res Tech 2002; 58: 619.
27. Slater RA, Ramot Y, Buchs A. The diabetic Charcot foot. Isr
46. Offley SC, Guo TZ, Wei T, Clark JD, Vogel H, Lindsey DP.
Med Assoc J 2004; 6: 2803.
Capsaicin-sensitive sensory neurons contribute to the mainte-
28. KorzonBurakowska A, Jakóbkiewicz-Banecka J, Fiedosiuk A,
nance of trabecular bone integrity. J Bone Miner 2005; 20:
Petrova N. Osteoprotegerin gene polymorphism in diabetic
25767.
Charcot neuroarthropathy. Diabet Med 2012; 29: 7715.
47. Akopian A, Demulder A, Ouriaghli F, Corazza F, Fondu P,
29. Nather A, Bee CS, Huak CY, Chew JLL. Epidemiology of
Bergmann P. Effects of CGRP on human osteoclast-like cell
diabetic foot problems and predictive factors for limb loss.
formation: a possible connection with the bone loss in neuro-
J Diabet Complications 2008; 22: 7782.
logical disorders? Peptides 2000; 21: 55964.
30. Petrova NL, Foster AV, Edmonds ME. Difference in presenta-
48. La Fontaine J, Harkless LB, Sylvia VL, Carnes D, Heim-Hall J,
tion of Charcot osteoarthropathy in type 1 compared with type Jude E. Levels of endothelial nitric oxide synthase and
2 diabetes. Diabetes Care 2004; 27: 12356. calcitonin gene-related peptide in the Charcot foot: a pilot
31. Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman study. J Foot Ankle Surg 2008; 47: 4249.
TR. The natural history of acute Charcot’s arthropathy in a 49. Blakytny R, Spraul M, Jude EB. Review: the diabetic bone: a
diabetic foot specialty clinic. J Am Pediatr Med Assoc 1997; 87: cellular and molecular perspective. Int J Low Extrem Wounds
2728. 2011; 10: 1632.
32. Pinzur MS. Benchmark analysis of diabetic patients with 50. Tan SD, Bakker AD, Semeins CM, Kuijpers-Jagtman AM,
neuropathic (Charcot) foot deformity. Foot Ankle Int 1999; Klein-Nulend J. Inhibition of osteocyte apoptosis by fluid flow
20: 5647. is mediated by nitric oxide. Biochem Biophys Res Commun
33. Chantelau E, Richter A, Schmidt-Grigoriadis P, Scherbaum 2008; 369: 11504.
WA. The diabetic Charcot foot: MRI discloses bone stres injury 51. Nilforoushan D, Gramoun A, Glogauer M, Manolson MF.
as trigger mechanism of neuroarthropathy. Exp Clin Endocrinol Nitric oxide enhances osteoclastogenesis possibly by mediating
Diabetes 2006; 114: 11823. cell fusion. Nitric Oxide 2009; 21: 2736.
34. Ndip A, Jude EB, Whitehouse R, Prescott M, Boulton AJ. 52. Baker N, Green A, Krishnan S, Rayman G. Microvascular and
Charcot neuroarthrtopathy triggered by osteomyelitis and/or C-fiber function in diabetic Charcot neuroarthropathy and
surgery. Diabet Med 2008; 25: 146972. diabetic peripheral neuropathy. Diabetes Care 2007; 30: 30779.
35. Giurato L, Uccioli L. The diabetic foot: Charcot joint and 53. Shapiro SA, Stansberry KB, Hill MA, Meyer MD. Normal
osteomyelitis. Nucl Med Commun 2006; 27: 7459. blood flow response and vasomotion in the diabetic Charcot
36. Aragón-Sánchez J, Lázaro-Martı́nez JL, Hernández-Herrero foot. J Diabetes Complications 1998; 12: 14753.
MJ. Triggering mechanisms of neuroarthropathy following 54. Schaper NC, Huijberts M, Pickwell K. Neurovascular control
conservative surgery for osteomyelitis. Diabet Med 2010; 27: and neurogenic inflammation in diabetes. Diabetes Metab Res
8447. Rev 2008; 24(Suppl 1): S404.
8
(page number not for citation purpose)
Citation: Diabetic Foot & Ankle 2013, 4: 21117 - http://dx.doi.org/10.3402/dfa.v4i0.21117
The Charcot foot
55. Childs M, Armstrong DG, Edelson GW. Is Charcot arthropathy morphisms and circulating OPG, soluble RANKL levels, and
a late sequela of osteoporosis in patients with diabetes mellitus? bone mineral density in Korean postmenopausal women.
J Foot Ankle Surg 1998; 37: 4379. Menopause 2007; 14: 9138.
56. Christensen TM, Bülow J, Simonsen L, Holstein PE, Svendsen 61. Pitocco D, Zelano G, Gioffrè G, Di Stasio E, Zaccardi F.
OL. Bone mineral density in diabetes mellitus patients with and Association between osteoprotegerin G1181C and T245G
without a Charcot foot. Clin Physiol Funct Imaging 2010; 30: polymorphisms and diabetic Charcot neuroarthropathy: a
1304. case-control study. Diabetes Care 2009; 32: 16947.
57. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits
NF-kB and MCP-1 expression in human aortic endothelial cells.
J Clin Endocrinol Metab 2001; 86: 4503. *Tahir Öğüt
58. Rogers LC, Frykberg RG, Armstrong DG, Boulton AJM, Cerrahpasa Faculty of Medicine
Edmonds M. The Charcot foot in diabetes. Diabetes Care Department of Orthopedics and Traumatology
2011; 34: 21239. Istanbul University
59. Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in TR-34303, Kocamustafapasa, Istanbul, Turkey
bone strength. Osteoporos Int 2006; 17: 31936. Tel: 90 532 564 84 09
60. Kim JG, Kim JH, Kim JY, Ku SY, Jee BC. Association between Fax: 90 212 414 3438
osteoprotegerin (OPG), receptor activator of nuclear factor- Email: drtahirogut@gmail.com
kappaB (RANK), and RANK ligand (RANKL) gene poly-